CoChat

Introduction to Drug Safety and Pharmacovigilance

Jose, Jimmy, Cox, Anthony R., Bate, Andrew · 2024 · Principles and Practice of Pharmacovigilance and Drug Safety

The DOI matches its Crossref record; 79 of the 79 references it cites were found in a registry or an index.

Overview

Integrity signals

Registry

Crossref · 10.1007/978-3-031-51089-2_1

Cites

79 of 79 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Research works printed but not linked: 16

  1. Rawlins MD. Pharmacovigilance: paradise lost, regained or postponed? The William Withering Lecture 1994. J R Coll Physicians Lond. 1995;29(1):41–9.
  2. Mann R, Andrew E. The Basis of pharmacovigilance: introduction. In: Mann R, Andrews E, editors. Pharmacovigilance. 2nd ed. Chichester: John Wiley and Sons Ltd; 2007. p. 3–11.
  3. Routledge P. 150 years of pharmacovigilance. Lancet (London, England). 1998;351(9110):1200–1. https://doi.org/10.1016/S0140-6736(98)03148. · doi:10.1016/s0140-6736(98)03148
  4. Stephens MD. The dawn of drug safety. Hampshire: George Mann; 2010.
  5. Shafique S. Thalidomide—an overview and the species-specific teratogenicity. Res J Congenit Dis. 2019;2:1.
  6. McBride WG. Thalidomide and congenital abnormalities. Lancet. 1961;2(1358):90927–8.
  7. Mohamed IN. Pharmacovigilance and reporting adverse drug reactions. Med Health. 2014;9(2):92–102.
  8. World Health Organization. International drug monitoring: the role of national centres. Technical report series no. 498. Geneva: WHO; 1972.
  9. International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. ICH Topic E 2 A clinical safety data management: definitions and standards for expedited reporting. 1995. Available at: https://www.ema.europa.eu/en/documents/scientific-guideline/international-conference-harmonisation-technical-requirements-registration-pharmaceuticals-human-use_en-15.pdf. Accessed 3 Aug 2022.
  10. Krska K, Cox AR. Adverse drug reactions. In: Whittlesea K, Hodson K, editors. Clinical pharmacy and therapeutics. 6th ed. Oxford: Elsevier; 2019.
  11. European Medicine Agency. Clinical safety data management: definitions and standards for expedited reporting. 1995. https://www.ema.europa.eu/en/documents/scientific-guideline/international-conference-harmonisation-technical-requirements-registration-pharmaceuticals-human-use_en-15.pdf.
  12. Dipiro CV. Obesity. In: Schwinghammer TL, Dipiro JT, Ellingrod VL, Dipiro CV, editors. Dipiro’s pharmacotherapy handbook. 12th ed. McGraw Hill; 2023. p. 657–6.
  13. Pichler WJ. Adverse side-effects to biological agents. Allergy. 2006;61(8):912–20. https://doi.org/10.1111/j.1398-9995.2006.01058. · doi:10.1111/j.1398-9995.2006.01058
  14. Ventola CL. Big data and pharmacovigilance: data mining for adverse drug events and interactions. P T. 2018;43(6):340–51.
  15. Dimbil M, Kyle R, Brown JS, Aldairy W. Using real-world data for rapid safety investigations: value of near-real-time clinical data querying. Drug Saf. 2022;45(10):1251–2.
  16. Frontiers in Pharmacology. Pharmacoinformatics: new developments and challenges in drug design. Available at: https://www.frontiersin.org/research-topics/50433/pharmacoinformatics-new-developments-and-challenges-in-drug-design. Accessed 23 Sept 2023.

Cited by

See all 3

Metadata

Authors
Jose, J., Cox, A. R., & Bate, A.
Affiliations
GlaxoSmithKline (United Kingdom) (GB)
Venue
Principles and Practice of Pharmacovigilance and Drug Safety
Published
2024
Pages
3-30
OpenAlex
W4401337825
Cited by
3
References
79
Citations by year
2026: 2 · 2025: 1
FWCI
6.02
Type
book chapter
Language
en
Open access
closed
Licence
Locations
Springer eBooks (publishedVersion)
Topics
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Patient Safety and Medication Errors
  • Health Sciences › Medicine › Geriatrics and Gerontology › Pharmaceutical Practices and Patient Outcomes
Keywords
drug safety, pharmacovigilance, adverse drug reactions, spontaneous reporting, post-marketing surveillance, real-world data, clinical trial limitations, medication errors, polypharmacy, pharmacoinformatics, artificial intelligence, pharmacogenomics, drug safety regulation, history of pharmacovigilance

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.